How sales of OTC pharmaceutical companies bigger so steady so long-.docVIP

 PAGE \* MERGEFORMAT 8 How sales of OTC pharmaceutical companies bigger so steady so long? Drugs are increasingly difficult to do more and more stringent national policy of ; terminal bar higher and higher; raw materials more expensive; staff salaries higher and higher; media costs more and more expensive; supply price of the more to lower; profit margins are increasingly thin; offices are increasingly difficult to manage; agents are increasingly disobedient; retail prices worsened the situation; consumers are increasingly disloyal to the (sales less and less) ... ... .. This is the candidate I work in Beijing recently, I heard several pharmaceutical companies, said the owner of the company up the status quo. It is true that there are a lot of these problems are not enterprise itself can change, such as: raw materials expensive, the policy strict management, media, high cost and low price pharmacy supplier. However, some problem is that agents are able to control, such as: agent management, the price system, maintenance, consumer loyalty, but only whether the method properly. Here, the combination of the author 10 years of pharmaceutical sales experience and the current OTC sales, and we discuss how to OTC products in the field of bigger, so steady, so long-standing problem. Most pharmaceutical companies no shortage of products, not lack of marketing ideas, some enterprises have gone as far as professional marketing plan marketing planning agency has done, from product positioning, to the price system, to the promotion strategy, there is a set of programs. Many enterprises do not lack of sales network, through independently owned offices recruit at all levels of agent model, mostly in the country established a sales network, and some companies even in the more than 2,000 agents across the country. But still facing the problem is getting lower and lower selling prices, sales of smaller and smaller. Although there are many drugs on television advertising, but